Pfizer Inc. (NYSE:PFE) Morgan Stanley 22nd Annual Global Healthcare Conference September 4, 2024 8:30 AM ET Company Participants David Denton - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Terence Flynn All right, great. We're going to get started here. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. Very pleased to be hosting Pfizer this morning, CFO, Dave Denton. I'm Terence Flynn from ...

Market Overview - Market volatility presents opportunities for investors to capitalize on discounted investment prospects, particularly in high-quality growth stocks facing price declines [1] - Economic concerns, including a potential U.S. economic slowdown and the Bank of Japan's interest rate hike, contribute to market turbulence [1] Investment Strategies - "Buying the dip" is a key value investing strategy that involves acquiring assets during market downturns, relying on thorough fundamental analysis [2] - Diversification across various sectors is essential to mitigate risk and align investments with financial goals and risk tolerance [2] Pfizer Analysis - Pfizer's stock has declined approximately 20% from its 52-week high, primarily due to concerns over falling COVID-19 vaccine sales [3] - The company has a diversified portfolio, including leading oncology drugs and a strategic $43 billion acquisition of Seagen, expected to add eight new drugs by 2030 [4] - Pfizer's second-quarter 2024 revenue exceeded $13 billion, marking a 3% operational increase year-over-year, with a 14% surge in revenue excluding COVID-19 products [4] - Key products like Vyndaqel and Nurtec ODT/Vydura have shown exceptional performance, with revenues increasing by 71% and 44% year-over-year, respectively [4] - Pfizer holds approximately $7 billion in cash reserves and offers a 5.89% dividend yield, indicating strong fundamentals and potential long-term growth [5] PayPal Analysis - PayPal commands approximately 40% of the global online payment processing market, with a recent stock price increase of 16% over the past month [7] - Despite trading 77% below its all-time high, PayPal's Q2 2024 revenue reached $7.9 billion, an 8% year-over-year increase, with operating income at $1.3 billion, a 17% increase [8] - Total payment volume expanded by 11% to nearly $417 billion, reflecting continued user engagement and strong cash flow generation [8][9] - PayPal's financial health is robust, with over $18 billion in cash and investments, positioning it as a compelling rebound play in the technology sector [9] SoFi Technologies Analysis - SoFi aims to be a leading platform for millennials in financial services, with a digital-first approach and a suite of products [11] - The company achieved $2.24 billion in revenue over the past year, with projected annual earnings growth of over 50% [12] - Despite recent profitability, SoFi's financial performance remains volatile, having reported a substantial net loss of $320 million in fiscal year 2022 [12][13] Conclusion - Pfizer, PayPal, and SoFi are potentially undervalued companies with strong fundamentals and growth prospects, making them attractive investment opportunities in a volatile market [14]

Through Pfizer Ignite, Acepodia will gain access to Pfizer's resources, scale and expertise as the company broadens the application of its platform beyond oncology into autoimmune diseasesPfizer Ignite will also provide strategic advisory support for Acepodia's ongoing clinical programs, ACE1831 in NHL and ACE2016 in solid tumorsAcepodia's lead ACC platform therapy has shown clinical benefits in oncology without the limitations of current CAR-T cell therapiesALAMEDA, Calif. and TAIPEI, Sept. 3, 2024 /PRNews ...

VLA15-221 Phase 2 study: strong immune response shown one month after a second booster dose (month 31) in pediatric and adult populationsSignificant anamnestic antibody response observed across all six serotypes, consistent with previous resultsFavorable safety profile of VLA15 observed in all age groups and for all vaccinations Saint-Herblain (France) and New York, NY, September 3, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) announced today positive immunogenicity and ...

A month has gone by since the last earnings report for Pfizer (PFE) . Shares have lost about 5.9% in that time frame, underperforming the S&P 500.Will the recent negative trend continue leading up to its next earnings release, or is Pfizer due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Q2 Earnings & Sales BeatPfizer’s second-quarter results were ...

Pfizer (PFE) is launching a new direct-to-consumer (DTC) website called PfizerForAll, which will allow patients to order its marketed products for COVID-19, influenza and migraine directly.How the New PFE Platform WorksThe digital pharmacy will offer a convenient home delivery option for Pfizer medicines through third-party pharmacies. The new website also provides access to scheduling same-day appointments with independent healthcare professionals, either in-person or online.PFE is also offering adult user ...

Major drug companies are increasingly going direct-to-consumer.Shares of beleaguered drug store and pharmacy chain Walgreens Boots Alliance (WBA -8.81%) fell 8.4% on Tuesday as of 3:22 p.m. ET.The reason for the drop today appears to be twofold: One, Pfizer unveiled its own direct-to-consumer telehealth and e-commerce platform. Two, Eli Lilly announced it would be cutting prices for its GLP-1 drug Zepbound by 50% for certain doses, when ordered directly from the drugmaker's LillyDirect e-commerce platform.W ...

Group 1: COVID-19 Vaccines Update - The FDA has approved updated mRNA-based vaccines from Pfizer and Moderna to address new COVID-19 strains, particularly targeting the KP.2 strain [2][3] - The KP.2 strain was dominant in May but now accounts for approximately 3% of U.S. cases, while KP.3 and its related strain KP.3.1.1 account for nearly 17% and almost 37% of cases, respectively [3] - The updated vaccines are expected to produce stronger immune responses against circulating variants compared to last year's vaccines [2] Group 2: Eligibility and Availability - The CDC recommends that everyone aged 6 months and older receive one dose of the new COVID-19 vaccine, with a suggested waiting period of two to three months since the last vaccination or infection [4] - Vaccination appointments are available at pharmacies, hospitals, and clinics, with Walgreens and CVS already scheduling appointments for early September [5][6] Group 3: Cost and Access - Most private insurance plans, as well as Medicare and Medicaid, cover the cost of COVID-19 vaccinations, while a federally-funded program provides free shots for children [8] - The CDC has allocated $62 million for state and local immunization programs to cover costs for uninsured and underinsured adults [8] Group 4: Novavax Vaccine - Novavax has filed for authorization of a new protein-based vaccine targeting the JN.1 strain, which is expected to provide protection against its descendants [9]

Its long-term growth plan just hit a small bump in the road.With Pfizer (PFE 0.42%) stock badly underperforming the market over the past three years, falling by 32% while the market rose by close to the same amount, the last thing shareholders want to hear is news of another setback. Alas, the latest stumble was a somewhat unexpected one, and now the company will probably not realize revenue from one of its programs.But is the stock still worth buying in hopes of a recovery over the long term? To answer tha ...

The FDA, on Aug 22, approved/authorized the updated mRNA-based COVID-19 vaccines of Pfizer (PFE) /BioNTech (BNTX) and Moderna (MRNA) that target the KP.2 strain of the virus.While the agency approved Pfizer/BioNTech’s Comirnaty and Moderna’s Spikevax for use in individuals aged 12 years of age and older, it granted emergency use authorization (EUA) to low-dose formulations of these vaccines for use in individuals aged six months through 11 years.These approvals/authorizations are based on a combination of m ...